Journal
NATURE REVIEWS CLINICAL ONCOLOGY
Volume 10, Issue 1, Pages 8-10Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrclinonc.2012.216
Keywords
-
Categories
Funding
- MRC [MC_U122861325] Funding Source: UKRI
- Cancer Research UK [15015] Funding Source: researchfish
- Medical Research Council [MC_U122861325] Funding Source: Medline
- Wellcome Trust [095626] Funding Source: Medline
Ask authors/readers for more resources
Patients with colorectal cancer with mutated PIK3CA, identified from two large observational cohorts, had increased cancer-specific and overall survival if they used aspirin regularly after diagnosis compared to non-users. No effect of aspirin was seen in patients with wild-type PIK3CA. Mutated PIK3CA might be a useful biomarker to select patients who would benefit from adjuvant aspirin therapy. Langley, R. E. & Rothwell, P. M. Nat. Rev. Clin. Oncol. 10, 8-10 (2013); published online 4 December 2012; doi:10.1038/nrclinonc.2012.216
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
